Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused?

Robert Kemp, Vinay Prasad

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: Surrogate outcomes are not intrinsically beneficial to patients, but are designed to be easier and faster to measure than clinically meaningful outcomes. The use of surrogates as an endpoint in clinical trials and basis for regulatory approval is common, and frequently exceeds the guidance given by regulatory bodies. Discussion: In this article, we demonstrate that the use of surrogates in oncology is widespread and increasing. At the same time, the strength of association between the surrogates used and clinically meaningful outcomes is often unknown or weak. Attempts to validate surrogates are rarely undertaken. When this is done, validation relies on only a fraction of available data, and often concludes that the surrogate is poor. Post-marketing studies, designed to ensure drugs have meaningful benefits, are often not performed. Alternatively, if a drug fails to improve quality of life or overall survival, market authorization is rarely revoked. We suggest this reliance on surrogates, and the imprecision surrounding their acceptable use, means that numerous drugs are now approved based on small yet statistically significant increases in surrogates of questionable reliability. In turn, this means the benefits of many approved drugs are uncertain. This is an unacceptable situation for patients and professionals, as prior experience has shown that such uncertainty can be associated with significant harm. Conclusion: The use of surrogate outcomes should be limited to situations where a surrogate has demonstrated robust ability to predict meaningful benefits, or where cases are dire, rare or with few treatment options. In both cases, surrogates must be used only when continuing studies examining hard endpoints have been fully recruited.

Original languageEnglish (US)
Article number134
JournalBMC Medicine
Volume15
Issue number1
DOIs
StatePublished - Jul 21 2017

Fingerprint

Biomarkers
Pharmaceutical Preparations
Marketing
Uncertainty
Quality of Life
Clinical Trials
Survival
Therapeutics

Keywords

  • Cancer
  • Outcomes
  • Regulation
  • Surrogate endpoints
  • US Food and Drug Administration (FDA)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Surrogate endpoints in oncology : When are they acceptable for regulatory and clinical decisions, and are they currently overused? / Kemp, Robert; Prasad, Vinay.

In: BMC Medicine, Vol. 15, No. 1, 134, 21.07.2017.

Research output: Contribution to journalArticle

@article{90acc0fc83644e508070fa904743bc41,
title = "Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused?",
abstract = "Background: Surrogate outcomes are not intrinsically beneficial to patients, but are designed to be easier and faster to measure than clinically meaningful outcomes. The use of surrogates as an endpoint in clinical trials and basis for regulatory approval is common, and frequently exceeds the guidance given by regulatory bodies. Discussion: In this article, we demonstrate that the use of surrogates in oncology is widespread and increasing. At the same time, the strength of association between the surrogates used and clinically meaningful outcomes is often unknown or weak. Attempts to validate surrogates are rarely undertaken. When this is done, validation relies on only a fraction of available data, and often concludes that the surrogate is poor. Post-marketing studies, designed to ensure drugs have meaningful benefits, are often not performed. Alternatively, if a drug fails to improve quality of life or overall survival, market authorization is rarely revoked. We suggest this reliance on surrogates, and the imprecision surrounding their acceptable use, means that numerous drugs are now approved based on small yet statistically significant increases in surrogates of questionable reliability. In turn, this means the benefits of many approved drugs are uncertain. This is an unacceptable situation for patients and professionals, as prior experience has shown that such uncertainty can be associated with significant harm. Conclusion: The use of surrogate outcomes should be limited to situations where a surrogate has demonstrated robust ability to predict meaningful benefits, or where cases are dire, rare or with few treatment options. In both cases, surrogates must be used only when continuing studies examining hard endpoints have been fully recruited.",
keywords = "Cancer, Outcomes, Regulation, Surrogate endpoints, US Food and Drug Administration (FDA)",
author = "Robert Kemp and Vinay Prasad",
year = "2017",
month = "7",
day = "21",
doi = "10.1186/s12916-017-0902-9",
language = "English (US)",
volume = "15",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Surrogate endpoints in oncology

T2 - When are they acceptable for regulatory and clinical decisions, and are they currently overused?

AU - Kemp, Robert

AU - Prasad, Vinay

PY - 2017/7/21

Y1 - 2017/7/21

N2 - Background: Surrogate outcomes are not intrinsically beneficial to patients, but are designed to be easier and faster to measure than clinically meaningful outcomes. The use of surrogates as an endpoint in clinical trials and basis for regulatory approval is common, and frequently exceeds the guidance given by regulatory bodies. Discussion: In this article, we demonstrate that the use of surrogates in oncology is widespread and increasing. At the same time, the strength of association between the surrogates used and clinically meaningful outcomes is often unknown or weak. Attempts to validate surrogates are rarely undertaken. When this is done, validation relies on only a fraction of available data, and often concludes that the surrogate is poor. Post-marketing studies, designed to ensure drugs have meaningful benefits, are often not performed. Alternatively, if a drug fails to improve quality of life or overall survival, market authorization is rarely revoked. We suggest this reliance on surrogates, and the imprecision surrounding their acceptable use, means that numerous drugs are now approved based on small yet statistically significant increases in surrogates of questionable reliability. In turn, this means the benefits of many approved drugs are uncertain. This is an unacceptable situation for patients and professionals, as prior experience has shown that such uncertainty can be associated with significant harm. Conclusion: The use of surrogate outcomes should be limited to situations where a surrogate has demonstrated robust ability to predict meaningful benefits, or where cases are dire, rare or with few treatment options. In both cases, surrogates must be used only when continuing studies examining hard endpoints have been fully recruited.

AB - Background: Surrogate outcomes are not intrinsically beneficial to patients, but are designed to be easier and faster to measure than clinically meaningful outcomes. The use of surrogates as an endpoint in clinical trials and basis for regulatory approval is common, and frequently exceeds the guidance given by regulatory bodies. Discussion: In this article, we demonstrate that the use of surrogates in oncology is widespread and increasing. At the same time, the strength of association between the surrogates used and clinically meaningful outcomes is often unknown or weak. Attempts to validate surrogates are rarely undertaken. When this is done, validation relies on only a fraction of available data, and often concludes that the surrogate is poor. Post-marketing studies, designed to ensure drugs have meaningful benefits, are often not performed. Alternatively, if a drug fails to improve quality of life or overall survival, market authorization is rarely revoked. We suggest this reliance on surrogates, and the imprecision surrounding their acceptable use, means that numerous drugs are now approved based on small yet statistically significant increases in surrogates of questionable reliability. In turn, this means the benefits of many approved drugs are uncertain. This is an unacceptable situation for patients and professionals, as prior experience has shown that such uncertainty can be associated with significant harm. Conclusion: The use of surrogate outcomes should be limited to situations where a surrogate has demonstrated robust ability to predict meaningful benefits, or where cases are dire, rare or with few treatment options. In both cases, surrogates must be used only when continuing studies examining hard endpoints have been fully recruited.

KW - Cancer

KW - Outcomes

KW - Regulation

KW - Surrogate endpoints

KW - US Food and Drug Administration (FDA)

UR - http://www.scopus.com/inward/record.url?scp=85025074701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025074701&partnerID=8YFLogxK

U2 - 10.1186/s12916-017-0902-9

DO - 10.1186/s12916-017-0902-9

M3 - Article

C2 - 28728605

AN - SCOPUS:85025074701

VL - 15

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 1

M1 - 134

ER -